Remifentanil Hydrochloride I · 1,536 days since initial FDA posting
Brand: ULTIVA
FDA lists Remifentanil Hydrochloride I as Active Shortage (Mylan Institutional, a Viatris Company).
Availability on file: Available
Remifentanil Hydrochloride Injection: Active Shortage
Available Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Remifentanil Hydrochloride Injection
- Manufacturer
- Mylan Institutional, a Viatris Company
- Dosage Form
- Injection
- Presentation
- Ultiva, Injection, 1 mg/1 mL (NDC 72078-034-01)
- Package NDC
- 72078-034-01
Status & Timeline
- Status
- Active Shortage
- Availability
- Available
- First Reported
- Jun 28, 2022
- Last Updated
- Mar 18, 2026
- Therapeutic Category
- Analgesia/Addiction
Row fields from the FDA Drug Shortages database via openFDA.
Nearby, Other Remifentanil Shortage Records
Remifentanil Hydrochloride Injection
Mylan Institutional, a Viatris Company
Injection
Remifentanil Hydrochloride Injection
Mylan Institutional, a Viatris Company
Injection
Remifentanil Hydrochloride Injection
Fresenius Kabi USA, LLC
Injection
Remifentanil Hydrochloride Injection
Fresenius Kabi USA, LLC
Injection
Remifentanil Hydrochloride Injection
Hikma Pharmaceuticals USA, Inc.
Injection
Remifentanil Hydrochloride Injection
Hikma Pharmaceuticals USA, Inc.
Injection